TL;DR
This study reveals that patients with small intestinal bacterial overgrowth (SIBO) experience significantly better outcomes from fecal microbiota transplantation (FMT) for chronic constipation compared to those without SIBO. The research highlights that the baseline microbial composition of the small intestine, rather than the colon, plays a crucial role in determining FMT efficacy.
What Problem Does This Paper Address?
Chronic constipation is a widespread and often debilitating condition. Fecal microbiota transplantation (FMT) has emerged as a promising therapeutic option, but its effectiveness can vary significantly between individuals. While the gut microbiome is known to be involved, previous research has largely overlooked the specific role of small intestinal bacterial overgrowth (SIBO) and the microbial state of the small intestine in influencing FMT outcomes for constipation. This paper aims to bridge this knowledge gap by investigating whether the presence of SIBO impacts the success of FMT in treating chronic constipation and how the small intestinal microbiome contributes to the restoration of colonic function.
Methods
The study employed a multi-faceted approach:
- Patient Cohort: 218 patients with chronic constipation were recruited. They were categorized into two groups based on a SIBO breath test: those with SIBO and those without (non-SIBO).
- FMT Intervention: All patients underwent FMT.
- Clinical Assessment: Constipation severity and quality of life were assessed using a battery of standardized questionnaires (Bristol Stool Form Scale, Constipation Assessment Scale, Constipation Scoring System, Patient Assessment of Constipation Symptoms, Patient Assessment of Constipation Quality of Life) before and after FMT.
- Microbiome Analysis: Fecal and small intestinal fluid samples were collected from patients before and at various time points after FMT. 16S rRNA gene sequencing was performed to analyze the microbial community composition.
- Bioinformatics and Statistical Analysis: Standard bioinformatics pipelines (Qiime2, DADA2) were used for sequence processing. Alpha and beta diversity analyses, LEfSe (Linear Discriminant Analysis Effect Size) for identifying differentially abundant taxa, and statistical tests (t-test, chi-squared test) were employed to compare groups and assess changes.
Datasets
The study utilized fecal and small intestinal fluid samples collected from 218 patients with chronic constipation. These samples were analyzed using 16S rRNA gene sequencing. The sequencing data has been uploaded to the National Center for Biotechnology Information (NCBI) platform under accession number PRJNA1099433.
Key Insights and Ideas
- SIBO as a Predictor of FMT Success: The presence of SIBO appears to be a positive indicator for FMT efficacy in chronic constipation. Patients with SIBO showed significantly higher cure and clinical response rates.
- Small Intestine Microbiome is Key: Unlike the colon, the small intestinal microbiome exhibited significant changes post-FMT and showed notable differences at baseline between the SIBO and non-SIBO groups. This suggests the small intestine's microbial environment is a critical determinant of FMT success.
- Specific Microbial Signatures: At baseline, SIBO patients had a higher abundance of Veillonella and lower abundances of Escherichia-Shigella and Acinetobacter in their small intestine compared to the non-SIBO group. These differences may explain the varied responses to FMT.
- Functional Implications: Preliminary functional predictions suggested stronger biosynthesis capabilities for isoleucine and valine in the SIBO group's small intestinal fluid, which could potentially enhance intestinal motility.
Key Results
- Clinical Efficacy: The SIBO group demonstrated a significantly higher cure rate (55.68% vs. 35.38%, P=0.003) and clinical response rate (80.68% vs. 55.38%, P=0.0001) compared to the non-SIBO group after FMT. The rate of non-response was significantly lower in the SIBO group (19.32% vs. 44.62%, P=0.0001).
- Symptom Improvement: Both groups showed significant improvements in bowel movement frequency, stool characteristics, and various constipation-related symptoms (abdominal, rectal, defecation) after FMT. However, the SIBO group generally scored better on these scales post-treatment.
- Microbiome Changes: While colonic microbiota showed minor changes post-FMT, the small intestinal microbiota underwent more substantial alterations. Specifically, the abundance of Escherichia-Shigella increased in both groups post-FMT, while Streptococcus and Veillonella decreased. In the SIBO group, Bifidobacterium showed a notable increase.
- Safety: FMT was found to be safe in both groups, with similar types and frequencies of adverse events (mostly mild, such as bloating and abdominal pain) that resolved with symptomatic treatment. No FMT-related deaths were reported.
Limitations and Future Work
The authors acknowledge several limitations:
- 16S rRNA Sequencing: The study relied on 16S rRNA sequencing, which provides taxonomic information but limited functional insights. Future work will involve metagenomic and metabolomic sequencing to gain a deeper understanding of microbial functions.
- Sample Collection Contamination: The method used for collecting small intestinal fluid (negative pressure device via nasojejunal tube) may have introduced some contamination. Improvements in sample collection techniques are planned.
The study opens avenues for further research into the specific microbial mechanisms underlying FMT efficacy in SIBO patients, particularly focusing on carbohydrate metabolism and the role of specific bacterial genera in restoring colonic homeostasis.
Summary updated